What is Dihexa? A Research Guide.

Dihexa belongs to a series of chemically modified angiotensin-IV-derived compounds. The 2013 paper describes metabolically stabilized analogues rather than an established medicine or a naturally occurring replacement peptide.[1]

The original development problem was chemical: angiotensin-IV-related peptides were vulnerable to degradation and had limited barrier permeability. Researchers modified a short structural core to change those properties. This explains why Dihexa is discussed as an engineered analogue rather than simply a natural peptide. The separate proposal that its effects depend on the HGF/c-Met system came from a paper whose record is now marked retracted; that proposal cannot be presented as a validated mechanism.[1][2]

The cited analogue research examines experimental biological activity and animal models. Work in these models can generate hypotheses about cognition-related pathways, but cannot establish improved memory or treatment of neurological disease in people.[1]

The 2013 publication describes chemically stabilized analogues and reports findings in scopolamine-impaired and aged rat models, including Morris water-maze performance and experimental synaptogenesis. Those are animal behaviour and laboratory endpoints, not tests in people with dementia. The 2014 mechanism paper is listed separately to make its retraction visible. Readers should distinguish the surviving preclinical report from a withdrawn mechanistic explanation rather than merging them into a single proven story.[1][2]

The widely cited HGF/c-Met mechanism paper is marked as retracted in its publication record. Its proposed mechanism must not be presented as reliable established evidence. Readers should check the current record, not rely on older summaries that omit this status.[1][2]

The remaining cited preclinical work does not establish human effectiveness or long-term safety. Listing a retracted paper here documents an evidence problem; it is not an endorsement of its findings.

The cited animal work does not establish a safe human exposure profile, long-term effects or clinical benefit. The retraction makes confidence in the frequently repeated mechanistic account especially problematic. Neither animal behaviour nor an experimental increase in synapse-related measurements establishes treatment of dementia or improved memory in healthy people.[1][2]